Monosan

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Monosan

Property Description
Active ingredient Isosorbide Mononitrate
Form Oral tablet (often sustained-release)
Pharmacological class Vasodilator; Organic Nitrate
Common use Prophylactic cardiovascular maintenance
Origin Synthetic compound

What Type of Medicine is Monosan?

Monosan is a prescription medicine fundamentally defined as an antianginal agent and a potent vasodilator utilized for the stable, long-term management of specific cardiovascular conditions. Its single active substance is the synthetic compound Isosorbide Mononitrate, which formally classifies it within the chemical group of organic nitrates. The drug is clinically recognized for its reliable pharmacological action; unlike certain related nitrates that rely on initial metabolic breakdown to become effective, Isosorbide Mononitrate is already in its active form. This structural feature ensures consistent and direct therapeutic availability.

Monosan’s Therapeutic Role and Pharmaceutical Form

The general purpose of Monosan is to decrease the overall effort and corresponding oxygen demand of the heart muscle, thereby helping to prevent the onset of discomfort associated with inadequate oxygen supply. It achieves this through a mechanism where it promotes the relaxation and widening of blood vessels (vasodilation), leading to a reduction in the pressure and volume of blood the heart must handle. The primary clinical purpose of Isosorbide Mononitrate is chronic symptom prophylaxis. This reinforces the medicine’s long-term role, which is crucial for patients requiring steady maintenance support. Monosan is commonly provided in the form of an oral tablet, frequently specified as a sustained-release or extended-release preparation. This specialized formulation ensures the medication is released slowly and consistently over many hours, which is necessary for the drug to provide the durable pharmacological effect critical for reliable maintenance therapy.

Regulatory References

  1. Isosorbide Drug Information | MedlinePlus

What side effects are possible with Monosan?

Possible side effects and safety information

The adverse reaction profile of Monosan (Isosorbide Mononitrate) is primarily reflective of its action as a potent vasodilator, consistent with official regulatory documentation.


Frequency-Classified Adverse Reactions

Side effects are classified by their official frequency of occurrence:

  • Very Common (affecting 1 in 10 patients or more): Headache.
  • Common (affecting up to 1 in 10 patients): Dizziness, Hypotension (low blood pressure), Tachycardia (increased heart rate), and Nausea.
  • Uncommon reactions include gastrointestinal effects such as vomiting and diarrhoea, along with flushing.

The most frequent adverse event, Headache, is often dose-dependent and is typically most pronounced at the beginning of treatment, diminishing with continued use. Regulatory documents also note that tolerance, or an attenuated effect, may develop with long-term, continuous exposure to the medicine.


Serious Events and Safety Restrictions

Safety documentation includes potential for Serious Adverse Reactions, such as episodes of Severe Hypotension which may lead to collapse, Syncope (fainting), and severe skin reactions like Exfoliative Dermatitis.

This medicine is subject to Mandatory Safety Restrictions and is contraindicated in specific clinical states. These include conditions associated with markedly low ventricular filling pressures (e.g., severe hypovolaemia) and conditions that obstruct blood outflow from the heart (e.g., severe aortic stenosis). Most critically, co-administration with Phosphodiesterase-5 (PDE-5) inhibitors is strictly contraindicated due to the risk of life-threatening cardiovascular collapse.

Overdose and Emergency Response

An overdose with Monosan (Isosorbide Mononitrate) results from an excessive pharmacological effect of the medication, primarily characterized by profound vasodilatation and severe hypotension leading to a reduced cardiac output. Officially documented signs of an overdose include a persistent throbbing headache, confusion, moderate fever, vertigo, palpitations, and syncope (fainting). Gastrointestinal effects such as nausea, vomiting, and bloody diarrhea are also noted presentations.

Individuals must seek immediate medical attention or contact emergency services if severe manifestations occur. Regulator guidance specifies that urgent medical help is required if the person collapses, experiences severe difficulty breathing, or if the lips, tongue, or skin suddenly appear blue or gray, which may indicate the life-threatening complication of methemoglobinemia.

Management described in regulatory documents is symptomatic and supportive. Treatment focuses on correcting hypotension by increasing central fluid volume using measures such as the passive elevation of the patient's legs or intravenous infusion of normal saline. The use of epinephrine or other arterial vasoconstrictors is stated as likely to do more harm than good. Methylene Blue is the specific antidote for treating methemoglobinemia.

Therapeutic Uses of Monosan

What Monosan Treats: Main Uses and Benefits

Monosan (Isosorbide Mononitrate) is a therapeutic agent generally used for the long-term preventative management of cardiovascular symptoms. Its applications are focused on managing symptoms associated with inadequate oxygen supply to the heart muscle, and it provides supportive relief when appropriate.

It is commonly used for the prophylactic (preventative) treatment of chronic stable angina pectoris due to coronary artery disease. This addresses symptom patterns characterized by recurrent chest discomfort, pressure, or tightness that is typically predictable and often brought on by physical exertion.

Taking the medication regularly may help to reduce the frequency and lessen the intensity of symptomatic episodes, thereby assisting with easing the overall symptom burden of the condition. Continuous therapy can support the patient's exercise tolerance and overall capacity for daily physical activity. By managing the predictable symptoms associated with heart effort, Monosan may assist with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Relevant for Chronic Stable Angina


Indications at a Glance

Monosan is commonly used for conditions involving chronic stable angina pectoris, specifically addressing the associated recurrent chest discomfort, symptoms that interfere with daily functioning, and predictable ischemic episodes where continuous symptomatic support is relevant.

Regulatory References

  1. DailyMed official FDA labeling

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory documentation defines specific populations and pre-existing conditions that determine eligibility for Monosan use. Only individuals who do not meet any of the established exclusion criteria are eligible for treatment.

Classification Status and Constraints (Official Labeling)
Absolute Contraindications Use is strictly prohibited for patients with known serious hypersensitivity to the active substance or excipients. Monosan is also contraindicated in patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Age-Group Rules Use is established for adults aged ge 18 years. Safety and efficacy have not been established in the pediatric population (patients under le 18 years), and use is generally not recommended in this group.
Organ Function Limitations Use requires special consideration, and may be not recommended or contraindicated in cases of severe hepatic impairment or severe renal impairment. Limited use or dose restriction may apply for less severe impairments.
Physiological Status Monosan is not recommended or contraindicated during pregnancy due to potential fetal harm documented in animal studies. Use is also generally not recommended during lactation (breastfeeding).

These official regulatory statements delineate the boundaries of safe and authorized use, ensuring the drug is only administered to populations where the benefit-risk profile has been formally evaluated.

What should I know about interactions with other medicines?

Monosan is strictly prohibited for co-administration with specific medicinal products classified as Contraindicated Combinations by regulatory authorities. This mandatory restriction applies to Phosphodiesterase Type 5 (PDE5) Inhibitors (e.g., Sildenafil, Tadalafil, Vardenafil) and the Soluble Guanylate Cyclase (sGC) Stimulator Riociguat. The prohibition is due to a severe, rapid pharmacodynamic interaction leading to an amplified risk of precipitous hypotension and associated cardiovascular events.

The interaction profile further describes Pharmacodynamic Hypotension Potentiation. Concurrent use with other blood pressure lowering agents, including beta-blockers, diuretics, and Calcium Channel Blockers, is documented to result in additive vasodilating effects. Specifically, co-administration with Calcium Channel Blockers is reported to cause marked symptomatic orthostatic hypotension.

Regarding other substances, consumption of Alcohol (Ethanol) is documented to potentiate the hypotensive effect, increasing the risk of severe postural symptoms. Official labeling also notes an Exposure-Altering Interaction where co-administration with Dihydroergotamine may increase the blood level of that drug. The absorption rate of Monosan is officially delayed by Food intake, though the total drug exposure is not altered. Regulatory information confirms that impaired hepatic or renal function has no major influence on the drug's pharmacokinetic properties in these populations.

Mechanism of Action

️ Molecular Mechanism and Hemodynamic Consequence

Monosan's mechanism is defined by its role as an organic nitrate, acting directly on the vascular smooth muscle. The active compound, Isosorbide Mononitrate, functions as an exogenous Nitric Oxide ( NO) donor, releasing a chemical signal into the local environment. This NO rapidly diffuses and targets the intracellular enzyme soluble Guanylate Cyclase ( sGC) inside the vascular smooth muscle cells.

Activation of sGC dramatically increases the production of the second messenger cyclic Guanosine Monophosphate ( cGMP). This cGMP-mediated cascade results in the relaxation of the smooth muscle and widespread vasodilation, which is most prominent in the veins (venodilation).

This physiological change leads to blood pooling in the peripheral capacitance vessels, which subsequently reduces the volume and pressure of blood returning to the heart, a key parameter known as preload. By decreasing venous return, the drug directly lessens the mechanical tension within the heart muscle walls. Continuous exposure to the compound can lead to a biological constraint known as nitrate tolerance, where the effectiveness of this mechanism is attenuated due to the depletion of cellular components required for NO release.

Dosage and Administration Information

How to Use Monosan

Monosan (Isosorbide Mononitrate) is administered strictly via the oral route for the long-term, preventative management of chronic cardiovascular symptoms. The core principle of its administration is adherence to a scheduled regimen that ensures a daily period without the medication to avoid the development of pharmacological tolerance.


Administration Details and Dosage Forms

Formulation Standard Dosing Regimen Administration Constraint
Immediate-Release (IR) Tablet Typically 20 mg taken twice daily. Doses are separated by approximately seven hours (e.g., 8 AM and 3 PM). Generally taken on an empty stomach.
Extended-Release (ER) Tablet Starting dose of 30 mg or 60 mg once daily, usually in the morning. Maintenance doses range up to 120 mg once daily. Must be swallowed whole and not crushed, chewed, or split to preserve the sustained-release mechanism.

Dosing Protocol and Special Populations

Treatment is intended for chronic, scheduled use, and is not intended for acute episodes. Dosage adjustments are made cautiously, with at least three days typically allowed between dose increases for extended-release forms. Due to the drug's intended purpose, the treatment should never be stopped abruptly; instead, the dosage must be gradually tapered when discontinuation is required.

For older adults, dose selection should be cautious and typically started at the lower end of the dosing range. For pediatric patients, the safety and effectiveness of Monosan have not been established.

Recent Clinical Evidence

Research evidence / Overview of studies for Monosan

Evidence for Use in Chronic Stable Angina Pectoris

Clinical evaluation for Monosan in chronic stable angina pectoris has primarily involved Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time, comparing the treatment being studied against an inactive control (placebo) or sometimes against other medicines used for similar conditions. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Specifically, studies explored functional capacity metrics related to exercise tolerance in adult patients with conditions characterized by fluctuating or episodic manifestations of chest discomfort.

Studies monitored changes measured during the study period, particularly focusing on episodes where symptoms become more noticeable. Research highlights changes measured in the patient's capacity to perform standardized exercise before the onset of chest discomfort. Studies monitored differences in measured exercise times between the group receiving Monosan and the placebo groups in short-term research. Further, research reports how symptoms evolved in the observed populations, with some studies describing a pattern of differences in the patient-reported weekly frequency of chest discomfort episodes.


Understanding Duration of Effect and Long-Term Studies

Because Monosan is often prescribed for long-term preventative management, research has explored the durability of the observed responses over extended time intervals. Research has explored whether patterns observed during long-term follow-up were associated with the use of dosing regimens that include a period without the medicine. This was monitored in trials exploring patterns of response over time. Data focusing on long-term functional changes and symptom patterns over many years is often derived from studies with limited follow-up intervals. Long-term effects are not fully established based on the highest level of evidence.


Areas of Research Uncertainty and Gaps

Follow-up durations were limited in the most rigorous studies, meaning long-term outcomes are not well characterized by RCTs. Evidence quality varies across studies, and there is limited information for long-term outcomes. The findings describe group patterns, not personal outcomes, and research provides context but not individual predictions about how any single patient will respond. Data for establishing patterns of use in pediatric patients (children and adolescents) remain insufficient.

Key Studies & References

  1. Label: ISOSORBIDE MONONITRATE tablet, extended release - DailyMed
  2. Label: ISOSORBIDE MONONITRATE tablet - DailyMed - NIH
  3. Isosorbide - StatPearls - NCBI Bookshelf - NIH

Frequently Asked Questions (FAQ)

Common questions about Monosan (FAQ)


Q: How quickly does Monosan usually start to work?

A: According to official product information, Monosan is used for long-term prevention of symptoms and is not intended for the relief of an acute, sudden episode. It is not a fast-acting medicine, and the sustained-release formulations are described as being designed to provide a steady, preventative effect over many hours for maintenance therapy.


Q: Is it common to feel tired after taking Monosan?

A: Official patient information often lists tiredness, fatigue, and dizziness as common side effects of Monosan, especially during the initial phase of treatment. These effects are generally described as consistent with the medicine's action as a vasodilator, which works by widening blood vessels. It is noted that these sensations may diminish with continued use.


Q: Can Monosan affect my sleep?

A: Some regulatory documents report that Monosan may cause uncommon side effects that could potentially affect sleep. These effects include restlessness or insomnia (difficulty sleeping). Persistent changes in sleep patterns are generally managed through consultation with a healthcare provider.


Q: What happens if I miss a dose of Monosan?

A: Regulatory guidance suggests that if a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped to avoid an over-exposure to the medicine. The regular dosing schedule is then resumed.


Q: Does Monosan interact with over-the-counter pain relievers?

A: Regulatory documents indicate that common pain relievers like acetaminophen or aspirin can successfully relieve headaches sometimes caused by Monosan. Official guidance often recommends consultation with a healthcare provider before combining prescription medicines with any new non-prescription medicines or supplements.


Q: Are there any foods I should avoid while using Monosan?

A: Official instructions do not typically require a special diet or list specific foods to avoid while using Monosan. The only specific substance warning is for alcohol (ethanol), which is documented to significantly increase the risk of low blood pressure when combined with this medicine. Official documentation describes maintaining a normal diet unless specific changes are recommended by a healthcare provider.


Q: Is Monosan known to cause allergic reactions?

A: Yes, Monosan is strictly contraindicated for individuals with a known serious hypersensitivity (allergic reaction) to the active substance, Isosorbide Mononitrate. Signs of a serious allergic reaction, such as a rash, hives, or swelling of the face, are conditions that should prompt contact with a medical professional.


Q: Are there any long-term health concerns linked to Monosan?

A: The official documentation primarily focuses on the potential for the body to develop nitrate tolerance and physical dependence with long-term, continuous use. This means the medicine's effectiveness may lessen over time, and stopping it suddenly can cause withdrawal symptoms. Tapering the dosage gradually is the method described in official documents when discontinuation is necessary.


Q: Does Monosan have a 'half-life' and what does that mean?

A: Monosan has a half-life, which is a term used in the drug’s pharmacokinetic data. The half-life is the time required for the concentration of the medicine in the blood to decrease by half. This information is key to determining the appropriate dosing schedule that provides a consistent effect and is contained within the full pharmacokinetic data.


Q: What should I do if the side effects of Monosan bother me?

A: Official guidance indicates that side effects that become bothersome or persistent are typically managed through consultation with a doctor or pharmacist. Official information states that the medicine should not be stopped or the dosage changed without the supervision of a healthcare provider.


Q: What are the rules about driving or operating machinery while on Monosan?

A: Official warnings advise caution regarding driving or operating heavy machinery while taking Monosan. This is due to potential side effects like dizziness, low blood pressure, and blurred vision that may occur, particularly when first starting treatment or when the dosage is adjusted.


Q: Is Monosan addictive or habit-forming?

A: Regulatory information notes that physical dependence and tolerance have been observed in some workers with high, long-term exposure to nitrates. While not a controlled substance, this is why official documentation describes the medicine as needing to be gradually tapered if it is stopped.


Q: When should I stop taking Monosan?

A: Monosan is typically prescribed for long-term maintenance and should not be stopped unless advised by a healthcare provider. Official labeling states that the medicine is not intended to be stopped abruptly. Instead, if discontinuation is necessary, the dosage is described as needing to be gradually reduced (tapered) under the supervision of a healthcare provider.


Q: Where can I find the official prescribing information for Monosan?

A: The official prescribing information for Monosan is publicly available on government-sponsored websites. Examples of these regulatory documents include the U.S. FDA Prescribing Information, the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), and the drug information sections of the NIH or MedlinePlus.


Q: Does Monosan have any known interactions with herbal supplements?

A: Official safety information advises that there is generally insufficient data to confirm the safety of complementary medicines, herbal remedies, and supplements when combined with Monosan. Official guidance recommends that all products, including herbal and non-prescription supplements, be fully disclosed to a healthcare provider.


Q: Is it okay to take Monosan if I have diabetes?

A: Official documentation does not list diabetes as an absolute contraindication. However, Monosan is a vasodilator, and caution is advised when combining it with other blood pressure lowering agents, which may include certain diabetes medications. Regulatory documents describe that this combination is documented to have an increased risk of additive hypotensive (low blood pressure) effects.


Q: Why is Monosan not recommended for people with [known contraindication]?

A: The reasons for restrictions are detailed in regulatory documents. For instance, the combination of Monosan with PDE5 inhibitors (like sildenafil) is strictly prohibited because their combined vasodilating effects can lead to life-threatening severe hypotension (dangerously low blood pressure). Other contraindications relate to the drug's mechanism of action, which is described as being able to worsen conditions such as heart outflow obstruction.


Q: Does Monosan expire quickly?

A: Official labeling specifies a defined shelf life for Monosan, which is typically several years (e.g., three years) when stored correctly. The medicine should not be used past the expiration date printed on the packaging.


Q: How does Monosan affect mental focus or alertness?

A: Official product information reports that side effects like dizziness, tiredness, and lack of concentration are possible with Monosan. Regulatory warnings concerning these effects are often tied to caution regarding activities that require full mental alertness, such as driving.

How should Monosan be stored and disposed of?

How to Store and Dispose of Monosan

Monosan (Isosorbide Mononitrate) must be stored strictly according to regulatory labeling to maintain its stability.

Official Storage Conditions

Requirement Official Instruction
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F).
Protection The product must be protected from moisture and stored with the container kept tightly closed.
Location Rule Must be stored out of the sight and reach of children. Avoid storage in high-humidity areas like bathrooms.

Disposal Instructions

Disposal of any unused or expired Monosan must follow local pharmaceutical waste guidelines. Official instructions are to dispose of the product according to local requirements. The medicine should not be flushed down a toilet or poured into a drain unless specifically advised by an authorized government program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Monosan found in:

A-Z Index: